Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ShK-Dap22 is a synthetic peptide analog of the ShK toxin, which was originally isolated from the sea anemone *Stichodactyla helianthus*. It is designed as a potent and highly selective blocker of the voltage-gated potassium channel Kv1.3 (KCNA3). The modification involves substituting the lysine residue at position 22 with diaminopropionic acid (Dap), a change that significantly enhances its selectivity for Kv1.3 over other closely related channels such as Kv1.1, Kv1.2, and Kv3.1. ShK-Dap22 is widely utilized as a pharmacological research tool to study the role of Kv1.3 channels in immune cell functions, particularly in effector memory T cells and natural killer (NK) cells. While primarily used in preclinical research, Kv1.3 blockers like ShK-Dap22 are investigated for their therapeutic potential in treating autoimmune diseases and modulating the tumor microenvironment in cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ShK-Dap22.